“When we see something that surprises us and flies in the face of what is understood, it requires another look — maybe a different cohort, larger numbers, longer follow-up,”
via Intensive Tx Fails to Slow Atherosclerosis | Medpage Today.
Surprised? As long as we continue to focus on pharmaceuticals as the answer, no one should be surprised.
Safety Information > February 2014.
Get to Know an Enzyme: CYP3A4.
I routinely check the FDA drug safety information for personal reasons. One thing led to another, thus the reason for the CYP3A4 link. If you like puzzles, try to figure out why I’m reading up on CYP3A4. My son the molecular biochemist soon to be MD would have no problem figuring this out.
The study included information from 135 randomized trials — 55 with a placebo control and 80 with an active comparator — that included a total of 246,955 participants with or without cardiovascular disease. The study initially included trials of atorvastatin, fluvastatin, simvastatin, lovastatin, pravastatin, and rosuvastatin (Crestor); trials of pitavastatin (Livalo) were added post hoc because the protocol was already being finalized at the time the drug was approved.
Conclusions – Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes.
via Risk of incident diabetes among patients treated with statins: population based study | BMJ.
…statin discontinuation is common and has been linked to a greater risk of heart-related events and death in patients who have coronary artery disease, the study said.
via Researchers suggest 2 paths to get patients back on statins – amednews.com.
One out of every four Americans over the age of 45 are on a statin.
Patients who took statins and were physically fit had as much as a 70% reduction in the risk of dying during the follow-up period as compared with the least physically fit patients who were taking statins, according to Peter Kokkinos, PhD, of George Washington University in Washington, and colleagues.
Physical fitness also had an independent effect on mortality risk among patients who were not taking statins, reducing the likelihood of death during follow-up by as much as 47%, they reported online in The Lancet.
via Statin-Exercise Combo Lowers Mortality Risk.
I really need to get the gym more often.
lifeunderwriter.net 
You must be logged in to post a comment.